Furthermore, we reported that post-ischemic treatment with antibodies neutralizing IL-1α and β reduce stroke size and improve post-stroke neurological deficit in mice undergoing tMCAO, by reducing post-ischemic BBB impairment through different pathways [139, 142]. The gene discussed is IL1A; the disease is stroke disorder.